Trials / Completed
CompletedNCT06804603
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
A Proof of Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight Class I or Class II Obese Volunteers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tradipitant | Oral capsule |
| DRUG | Placebo | Oral capsule |
Timeline
- Start date
- 2025-02-25
- Primary completion
- 2025-10-06
- Completion
- 2025-10-06
- First posted
- 2025-02-03
- Last updated
- 2025-11-12
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06804603. Inclusion in this directory is not an endorsement.